July 23, 2017 5:12 PM ET

Life Sciences Tools and Services

Company Overview of Kailos Genetics, Inc.

Company Overview

Kailos Genetics, Inc., a personalized medicine information company, provides gene-based testing services for clinicians and researchers. It offers TargetRich, a technology that enables analysts to separate genes of interest from unimportant background DNA; Kailos Blue end-to-end software suite; and products for research use and reference lab services. The company also develops carrier screening tests for parents; and tests covering various medical conditions. In addition, it offers its tests for people concerned about health, people starting new medicines, and families planning to have children. The company sells its tests online. Kailos Genetics, Inc. was founded in 2010 and is based in Hun...

601 Genome Way

Suite 3005

Huntsville, AL 35806-2908

United States

Founded in 2010



Key Executives for Kailos Genetics, Inc.

Chairman, Chief Executive Officer and President
Chief Financial Officer and Senior Vice President of Corporate Development
Chief Strategy Officer, Treasurer and Director
Chief Technology Officer
Chief Scientific Officer, Secretary and Director
Compensation as of Fiscal Year 2017.

Kailos Genetics, Inc. Key Developments

Kailos Genetics Announces Co-Marketing Agreement with Illumina, Inc. for Pharmacogenetics Solution for Research

Kailos Genetics announced it has entered into a co-marketing agreement with Illumina, Inc. Under the terms of the agreement, Illumina will market and promote the Kailos TargetRich™ line of research solutions for pharmacogenetics targets through its commercial channels. Kailos research solutions under the agreement include: TargetRich PGxComplete™ and Kailos Blue™. TargetRich PGxComplete™ is a research use-only reagent that targets a spectrum of relevant genes and provides insights on effectiveness of more than 100 medications based on the resulting genotype. Kailos Blue is the company’s automated data analysis solution – built with one of the industry’s most advanced computing – and reporting software for using TargetRich reagents. As an Illumina BaseSpace Suite® ecosystem partner, the solution integrates with and pulls data from BaseSpace Sequence Hub which enables customers to, in real-time, stream their data directly from the sequencing instrument. TargetRich’s automated approach uses a single tube from start to finish with addition-only protocol, which results in a hands-on time of only 75 minutes. The use of unique molecular identifiers offers extremely high levels of sequence quality analysis, delivering results from research experiments at a low cost per targeted base pair.

Kailos Genetics Announces Release of PGxComplet

Kailos Genetics announced the release of PGxComplete, a comprehensive, full panel, gene-based test offered at $99 through November 30, 2015, a test that traditionally sells for hundreds or even thousands of dollars. By further reducing their already low cost full panel test, Kailos is able to give consumers greater access to affordable genetic testing, ultimately giving them the power to make more informed decisions about their health. The full panel tests 20 different classes of medications to reveal how one’s body responds to more than 50 types of medications, including antidepressants, opioids, HIV/AIDS treatment and cancer therapy. By understanding how one’s body metabolizes these medicines, each person can take greater control over their own health helping to avoid overdose, select the most effective medications and receive the desired results from treatment. PGxComplete gives people the tools needed to work with their physician to select the right medication and dosage combination based on their DNA. This helps ensure that they are getting the desired effects of treatment. The company developed the PGxComplete test using advanced technology that harnesses DNA sequencing and enables a more holistic view of a person’s gene-based medical information.

Kailos Genetics Hires Cheri Walker as Chief Financial Officer and Senior Vice President of Corporate Development

Kailos Genetics, Inc. announced the expansion of its senior management team through the addition of experienced life science industry veteran Cheri Walker, PhD as chief financial officer and senior vice president of corporate development. With more than 18 years of experience in the life science and diagnostic market, Dr. Walker will support Kailos Genetics with a strong combination of technical and financial skills. She will draw on expertise gained from her work as an equity analyst for Deutsche Bank and through senior level corporate development and operating roles at Invitrogen, QIAGEN and Charles River Labs. Dr. Walker also served on the board of directors of Diatherix Laboratories, Inc.

Similar Private Companies By Industry

Company Name Region
10X Genomics, Inc. United States
4G Clinical, Inc. United States
AAPharmaSyn LLC United States
Abiant, Inc. United States
aBioBot, Inc. United States

Recent Private Companies Transactions

Private Placement
July 11, 2017
Private Placement
November 16, 2016

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Kailos Genetics, Inc., please visit www.kailosgenetics.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.